Results 231 to 240 of about 215,645 (266)
Some of the next articles are maybe not open access.
2016
Acute ischemic stroke is common and often treatable, but treatment requires reliable information on the state of the brain that may be provided by modern neuroimaging. Critical information includes: the presence of hemorrhage; the site of arterial occlusion; the size of the early infarct "core"; and the size of underperfused, potentially threatened ...
R Gilberto, González, Lee H, Schwamm
openaire +2 more sources
Acute ischemic stroke is common and often treatable, but treatment requires reliable information on the state of the brain that may be provided by modern neuroimaging. Critical information includes: the presence of hemorrhage; the site of arterial occlusion; the size of the early infarct "core"; and the size of underperfused, potentially threatened ...
R Gilberto, González, Lee H, Schwamm
openaire +2 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
Stroke is the third most common cause of death in the United States and is the number one cause of long‐term disability. Legislative mandates, largely the result of the American Heart Association, American Stroke Association, and Brain Attack Coalition working cooperatively, have resulted in nationwide standardization of care for patients who ...
Kathleen, Baldwin +5 more
openaire +2 more sources
Stroke is the third most common cause of death in the United States and is the number one cause of long‐term disability. Legislative mandates, largely the result of the American Heart Association, American Stroke Association, and Brain Attack Coalition working cooperatively, have resulted in nationwide standardization of care for patients who ...
Kathleen, Baldwin +5 more
openaire +2 more sources
Management of Acute Ischemic Stroke
Seminars in Respiratory and Critical Care Medicine, 2002Prior to 1995 no proven therapy existed for acute ischemic stroke. In 1996 the U.S. Food and Drug Administration approved the use of intravenous rt-PA in acute stroke based largely on the results of a two-part trial sponsored by the National Institutes of Health and National Institute of Neurological Disorders and Stroke (NIH/NINDS).
openaire +2 more sources
Cyclosporine in acute ischemic stroke
Neurology, 2015We examined whether IV administration of cyclosporine in combination with thrombolysis might reduce cerebral infarct size.Patients aged 18 to 85 years, presenting with an anterior-circulation stroke and eligible for thrombolytic therapy, were enrolled in this multicenter, single-blinded, controlled trial.
Nighoghossian, N. +30 more
openaire +3 more sources
Expert Review of Cardiovascular Therapy, 2010
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up ...
Henninger, Nils +2 more
openaire +3 more sources
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up ...
Henninger, Nils +2 more
openaire +3 more sources
Acute Ischemic Stroke and Infections
Journal of Stroke and Cerebrovascular Diseases, 2011We present an overview of multiple infections in relation to acute ischemic stroke and the therapeutic options available. Conditions that are a direct cause of stroke (infectious endocarditis, meningoencephalitides, and human immunodeficiency virus infection), the pathophysiologic mechanism responsible for stroke, and treatment dilemmas are presented ...
Catalina C, Ionita +5 more
openaire +2 more sources
Alteplase for acute ischemic stroke
Expert Review of Cardiovascular Therapy, 2006Alteplase, an intravenously administered form of recombinant tissue plasminogen activator (rt-PA), remains the only US FDA-approved thrombolytic treatment for acute ischemic stroke within 3 h of symptom onset. Patients treated with intravenous rt-PA are at least 30% more likely to have minimal or no disability at 3 months compared with placebo. Despite
Nicole R, Gonzales, James C, Grotta
openaire +2 more sources
Immunothrombosis in Acute Ischemic Stroke
StrokeIschemic stroke is one of the leading causes of disability and mortality worldwide. Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention. In recent years, with the development of endovascular treatment and therefore retrieving the thrombus for further investigation, evidence is ...
Yan Wang +4 more
openaire +2 more sources
Neuroprotection in acute ischemic stroke.
Acta neurologica Belgica, 2005Neuroprotection of patients with acute ischemic stroke should start at the scene and continue in the ambulance with the assessment and treatment of the airway, breathing, circulation, body temperature, and blood glucose. The key goal in eligible patients should be fast vessel recanalization with intravenous recombinant tissue-type plasminogen activator
De Keyser, Jacques +6 more
openaire +2 more sources
Thrombectomy in Acute Ischemic Stroke
New England Journal of Medicine, 2022David C. Lauzier, Akash P. Kansagra
openaire +2 more sources